Chimerix (NASDAQ:CMRX) Receives “Hold” Rating from Jefferies Financial Group

Jefferies Financial Group reaffirmed their hold rating on shares of Chimerix (NASDAQ:CMRX) in a research report report published on Wednesday morning,Benzinga reports. Jefferies Financial Group currently has a $8.50 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $10.00.

Several other research firms also recently weighed in on CMRX. Wedbush restated a “neutral” rating and issued a $8.55 price objective (up from $7.00) on shares of Chimerix in a report on Wednesday. HC Wainwright restated a “neutral” rating and issued a $8.55 price objective (down from $11.00) on shares of Chimerix in a report on Wednesday.

Chimerix Price Performance

CMRX stock opened at $8.46 on Wednesday. The business has a 50-day moving average price of $4.04 and a 200 day moving average price of $2.17. The company has a market capitalization of $760.86 million, a P/E ratio of -9.00 and a beta of 0.32. Chimerix has a 1-year low of $0.75 and a 1-year high of $8.47.

Insiders Place Their Bets

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders sold 20,760 shares of company stock worth $91,175. 13.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Chimerix

A number of large investors have recently added to or reduced their stakes in the company. Stoneridge Investment Partners LLC raised its holdings in Chimerix by 22.5% in the fourth quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 8,134 shares in the last quarter. Bender Robert & Associates purchased a new stake in shares of Chimerix during the fourth quarter worth about $37,000. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Chimerix during the fourth quarter worth about $59,000. Jane Street Group LLC purchased a new stake in shares of Chimerix during the fourth quarter worth about $62,000. Finally, Diadema Partners LP purchased a new stake in shares of Chimerix during the fourth quarter worth about $101,000. 45.42% of the stock is currently owned by institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.